Brokerages predict that Retrophin Inc (NASDAQ:RTRX) will report earnings per share (EPS) of ($0.08) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Retrophin’s earnings. The lowest EPS estimate is ($0.19) and the highest is $0.04. Retrophin posted earnings of $0.03 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 366.7%. The company is expected to issue its next quarterly earnings results on Wednesday, August 8th.
On average, analysts expect that Retrophin will report full-year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.80) to $0.33. For the next year, analysts anticipate that the business will report earnings of $0.53 per share, with EPS estimates ranging from $0.41 to $0.65. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Retrophin.
Retrophin (NASDAQ:RTRX) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.25). Retrophin had a negative net margin of 41.95% and a negative return on equity of 20.27%. The company had revenue of $38.43 million during the quarter, compared to analyst estimates of $39.32 million. During the same quarter in the previous year, the firm earned $0.01 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis.
RTRX has been the subject of a number of research reports. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research note on Saturday, March 3rd. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Finally, BMO Capital Markets decreased their target price on Retrophin from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Wednesday, April 4th.
Retrophin traded up $0.92, reaching $28.81, during midday trading on Friday, MarketBeat.com reports. The company had a trading volume of 666,578 shares, compared to its average volume of 305,989. The company has a quick ratio of 4.98, a current ratio of 5.07 and a debt-to-equity ratio of 0.15. Retrophin has a fifty-two week low of $17.52 and a fifty-two week high of $29.77. The company has a market cap of $1.15 billion, a P/E ratio of -19.21 and a beta of 1.06.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank raised its holdings in shares of Retrophin by 6.7% during the first quarter. Swiss National Bank now owns 63,700 shares of the biopharmaceutical company’s stock valued at $1,424,000 after buying an additional 4,000 shares during the last quarter. Emory University raised its holdings in shares of Retrophin by 14.8% during the fourth quarter. Emory University now owns 84,885 shares of the biopharmaceutical company’s stock valued at $1,789,000 after buying an additional 10,968 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Retrophin by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 76,988 shares of the biopharmaceutical company’s stock valued at $1,622,000 after buying an additional 18,314 shares during the last quarter. Consonance Capital Management LP raised its holdings in shares of Retrophin by 4.0% during the fourth quarter. Consonance Capital Management LP now owns 3,644,438 shares of the biopharmaceutical company’s stock valued at $76,788,000 after buying an additional 138,834 shares during the last quarter. Finally, Spark Investment Management LLC raised its holdings in shares of Retrophin by 13.3% during the fourth quarter. Spark Investment Management LLC now owns 327,800 shares of the biopharmaceutical company’s stock valued at $6,906,000 after buying an additional 38,500 shares during the last quarter.
Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Get a free copy of the Zacks research report on Retrophin (RTRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.